T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial
Lisa Blixt, David Wullimann, Soo Aleman, Jeanette Lundin, Puran Chen, Yu Gao, Angélica Cuapio, Mira Akber, Joshua Lange, Olga Rivera‐Ballesteros, Marcus Buggert, Hans‐Gustaf Ljunggren, Lotta Hansson, Anders Österborg
Abstract
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial *Ab baseline = 0.4 U/mL; seropositive >0.8 U/mL. a n = 48 (with d35 data). Ab: antibodies; ELISpot: enzyme-linked
Topics & Concepts
MedicineChronic lymphocytic leukemiaClinical trialSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Immune systemCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakVaccinationImmunologyImmunotherapyOpen labelLeukemiaVirologyInternal medicineDiseaseOutbreakInfectious disease (medical specialty)Cancer Immunotherapy and BiomarkersSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies